Sofosbuvir
Top View
- Sofosbuvir with Daclatasvir and the Outcomes of Patients with COVID-19
- EPCLUSA (Sofosbuvir and Velpatasvir)
- GLASS Methodology for Surveillance of National Antimicrobial Consumption
- Tablets SOVALDI® (Soh-VAHL-Dee) (Sofosbuvir) Oral Pellets Important
- Harvoni® (Ledipasvir/Sofosbuvir) & Ribavirin Treatment Agreement
- Ledipasvir/Sofosbuvir (Harvoni®) Drug Interactions a Quick Guide For
- HEPATITIS C AGENTS Epclusa (Sofosbuvir & Velpatasvir), Harvoni
- HARVONI® Safely and Effectively
- Summary: Patients with HIV/HCV Coinfection from on September 24, 2021
- Sofosbuvir for COVID‑19 Infection: a Potential Candidate
- Sofosbuvir-Velpatasvir-Voxilaprevir (Vosevi)
- Sofosbuvir: the fi Nal Nail in the Coffi N for Hepatitis C?
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- SOVALDI (Sofosbuvir) Tablets, for Oral Use Symptomatic Bradycardia May Occur in Patients Taking Initial U.S
- Search for SARS-Cov-2 Inhibitors in Currently Approved Drugs to Tackle COVID-19 Pandemia
- Olysio (Simeprevir)
- Olysio® (Simeprevir) & Sovaldi® (Sofosbuvir) Treatment Agreement
- Treatment of HCV Genotype 4